Japanese jornal of Head and Neck Cancer
Online ISSN : 1883-9878
Print ISSN : 0911-4335
ISSN-L : 0911-4335
Adenoid Cyctic Carcinoma in the Head and Neck
A Clinical Study of 30 cases
Sohei ENDOAkinori KIDATohru FURUSAKAHidenobu IIDAYoichiro YAMADAShuntaro SHIGIHARAHidetoshi KAWAMOTOMitsuyoshi OOKIKenichi AISOMasahide YASUDAHidefumi NAKAZATOHiroshi TOMITATomoyuki MIYAKAWAIsamu SAKURAI
Author information
JOURNAL FREE ACCESS

1989 Volume 15 Issue 2 Pages 48-52

Details
Abstract
30 cases of adenoid cystic carcinoma (ACC) in the head and neck region were studied. They were arising in 13 major salivary glands (parotid 5, submandibular 4, sublingual 4), 9 nose and paranasal sinuses (maxilla 3, maxilloethmoid 1, ethmoid 3, sphenoid 1, nasal cavity 1), 5 oral cavities (tongue base 2, floor of the mouth 2, palate 1), 1 larynx, 1 external auditory canal, and 1 unkown. The presenting symptoms were a mass without pain in 25%, mass with pain in 17.9%, and pain in 17.9%. Mean duration of symptoms was 22 months. Only three patients had Stage I, each seven patients had Stage II or III, and 13 patients had Stag IV. 23.3% of the patients died of disease, with a mean survival period of 44 months. Histologic specimens were reviewed and divided into 3 subtypes-tubular, cribriform, and solid. 3 patients had tubular subtype, 22 and 5 patients had cribriform and solid subtype. In 25 out of 28 treated cases surgery was done, with 9 of them considered as curative one. Combination chemotherapy with cyclophosphamide, adriamycin, and cis-platinum was done in 9 cases with a response rate of 11.1% (1/9). Radiation therapy was done in 8 cases in total with a response rate of 100% (2/2). Radiation therapy accompanied with chemotherapy containing cis-platium was done in 2 cases with a response rate of 50% (1/2). Cumulative survival rate for 5 and 10 year was 50% (8/16) and 16.7% (1/6) respectively. Factors which appeared to influence the clinical course included 1) presense or absence of metastasis, 2) clinical stage, with absenseof metastasis, and lower clinical stage to have better prognosis.
Content from these authors
© Japan Society for Head and Neck Cancer
Previous article Next article
feedback
Top